Table 3.
Clinical outcomes
| Transfem GA (n=51)(%) | Transfem LASedation (n=66) (%) | Transapical (n=59) (%) | |
|---|---|---|---|
| Major cardiovascular complications | 2 (4) | 4 (6) | 17 (29)* |
| Renal replacement therapy | 0 | 0 | 5 (8)** |
| Acute kidney injury | 8 (16) | 7 (11) | 16 (27) |
| CVA and or TIA | 2 (4) | 2 (3) | 7 (12) |
| Bleeding complications | 5 (10) | 2 (3) | 6 (10) |
| Moderate AR | 9 (18) | 9 (14) | 6 (10) |
| Vascular complications | 15 (29)* | 5 (7) | 5 (8) |
| Infectious complications | 11 (22) | 0* | 18 (31) |
| Permanent pacemaker | 0 | 10 (15)*** | 3 (5) |
| Pulmonary complications | 4 (8) | 1 (2) | 10 (17)** |
| Delirium | 16 (31) | 16 (24) | 14 (24) |
| Conduction abnormalities | 14 (27) | 21 (32) | 19 (32) |
| In-hospital mortality | 1 (2) | 2 (3) | 9 (15)* |
| 30 day mortality | 1 (2) | 3 (5) | 10 (17)* |
All data are expressed in numbers (%). *P<0.05: Compared with other two groups, **P<0.05: Transapical versus transfem LASedation, ***P<0.05: In-between transfemoral groups. Transfem GA: Transfemoral general anesthesia, Transfem LASedation: Transfemoral local anesthesia±sedation, CVA: Cerebrovascular accident, TIA: Transient ischemic attack, AR: Aortic regurgitation